MAIA Stock — MAIA Biotechnology Inc.: Cash, EV, Pipeline

Share price

$1.31

Market cap

$79.7M

Cash

$0.0M

Enterprise value

$79.7M

Balance sheet

Cash	$0.0M
Debt	$0.0M
Net cash	$0.0M
Enterprise value	$79.7M
Basic shares	60.8M shares
Fully diluted shares	102.0M shares
Fully diluted market cap	$133.6M
Cash per share	$0.00

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading MAIA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Sep 11 - Oct 23	6-Thio-2'-Deoxyguanosine	Phase 3	Carcinoma, Non-Small -Cell Lung	—
Nov 11 - Dec 23	6-Thio-2'-Deoxyguanosine	Phase 2	Carcinoma, Non-Small-Cell Lung	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ateganosine

Phase 3 · Active Modality: small molecule (telomere-targeting nucleoside analog)

Aliases THIO, 6-thio-2'-deoxyguanosine, 6-thio-dG

Target telomeres / telomerase

Partnerships Regeneron (THIO-101 NSCLC trial with cemiplimab); BeOne Medicines (planned THIO-102 trials with tislelizumab in HCC, SCLC and CRC; BeOne funds trials and provides tislelizumab); Roche (trials with atezolizumab); UTSW (exclusive worldwide license to THIO; second license to additional compound)

Indications

Third-line non-small cell lung cancer (NSCLC) (Phase 3)
NSCLC resistant to checkpoint inhibitors and chemotherapy (Phase 2)
Hepatocellular carcinoma (HCC) (Phase 2)
Small cell lung cancer (SCLC) (Phase 2)
Colorectal cancer (CRC) (Phase 2)
Other solid tumors (breast, prostate, gastric, pancreatic) (Discovery)

Status note Lead asset. Phase 3 THIO-104 pivotal trial in 3L NSCLC; first patient dosed December 2025. Phase 2 THIO-101 in NSCLC Parts A/B/C; Part C international enrollment completed June 2026. FDA Fast Track designation for NSCLC (July 2025).

Second-generation ateganosine prodrugs

Discovery · Active Modality: small molecule (telomere-targeting)

Aliases MAIA-2021-20, MAIA-2022-12

Target Telomere

Indications

Cancer (relapsed and refractory) (Discovery)

Status note Pipeline of seven compounds that completed in vitro evaluation; lead MAIA-2021-20 and backup MAIA-2022-12 nominated for GLP-toxicity and other preclinical studies, with Phase 1 trials planned.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	6-Thio-2'-Deoxyguanosine
Lead indication	Carcinoma, Non-Small -Cell Lung
Lead phase	Phase 3
Active trials	2
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06908304	Phase 3	Recruiting	Sponsor	Maia Biotechnology	—	Carcinoma, Non-Small -Cell Lung	—
NCT05208944	Phase 2	Active, not recruiting	Sponsor	Maia Biotechnology	—	Carcinoma, Non-Small-Cell Lung	—
NCT07446257	Early Phase 1	Recruiting	Collaborator	University of Texas Southwestern Medical Center	—	Resectable Hepatocellular Carcinoma	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Maia Biotechnology on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

MAIA — MAIA Biotechnology Inc.